Whalesbook
Aarti Drugs Ltd has reported its audited financial results for the fiscal year ended March 31, 2026. The company announced consolidated revenue of ₹2,565.31 crore and a profit after tax (PAT) of ₹194.94 crore for the full year.
For the fourth quarter (Q4 FY26), consolidated revenue stood at ₹720.30 crore, with PAT at ₹55.26 crore. On a standalone basis, the company recorded revenue of ₹2,260.39 crore and PAT of ₹157.31 crore for the fiscal year.
The Board of Directors also confirmed key governance appointments. M/s GMVP & Associates LLP was re-appointed as Cost Auditor for FY27. M/s Raman S. Shah & Co. will continue as Internal Auditor for the next three fiscal years. Additionally, the Risk Management Committee was re-constituted, with Shri Narendra J. Salvi joining as a member.
This performance represents growth compared to the previous fiscal year. For the year ended March 31, 2025, Aarti Drugs had reported consolidated revenue of approximately ₹2,475 crore and PAT of around ₹175 crore. Standalone revenue for FY25 was ₹2,100 crore with PAT at ₹145 crore.
Aarti Drugs operates as a key player in India's pharmaceutical sector, specializing in Active Pharmaceutical Ingredients (APIs) and intermediates. The company has focused on capacity expansion and backward integration to strengthen its supply chain and competitive position in the market.
Investors will monitor potential challenges, including volatility in raw material prices which can affect manufacturing costs and profit margins. Intensifying competition in the API and specialty chemicals market may also exert pricing pressure. The company must continue adapting to stringent regulatory compliance requirements in both domestic and international markets.
Aarti Drugs competes in the API and pharmaceutical intermediates space with companies like Divi's Laboratories and Laurus Labs. These peers navigate similar market dynamics, including raw material sourcing, price fluctuations, and evolving global regulatory standards.
Looking ahead, investors will seek insights from management commentary on future growth drivers and the company's outlook during upcoming earnings calls. Key areas of interest include guidance on capital expenditure plans for expansion, the performance of major product segments, emerging market share trends, and the impact of regulatory changes. Progress on backward integration initiatives and their contribution to cost efficiencies will also be closely monitored.